Literature DB >> 8438092

Toxicology of daily administration to mice of the radiation potentiator SR 4233 (WIN 59075).

J F Spiegel1, M A Spear, J M Brown.   

Abstract

We have investigated the feasibility of administration of an effective dose of the hypoxic cytotoxin, SR 4233, Monday-Friday daily for 6 weeks. From a thorough hematological, histopathological and clinical chemistry evaluation throughout the course and during a 3-week recovery period, we conclude that daily administration of a radiopotentiating dose of SR 4233 in mice is well tolerated and that bone marrow suppression is likely to be the dose-limiting toxicity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8438092     DOI: 10.1016/0167-8140(93)90031-3

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  2 in total

1.  The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours.

Authors:  E Lartigau; M Guichard
Journal:  Br J Cancer       Date:  1996-06       Impact factor: 7.640

Review 2.  SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours.

Authors:  J M Brown
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.